Hsbc Holdings PLC Makes New $5.25 Million Investment in Bruker Corporation $BRKR

Hsbc Holdings PLC purchased a new position in shares of Bruker Corporation (NASDAQ:BRKR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 88,647 shares of the medical research company’s stock, valued at approximately $5,252,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BRKR. Wellington Management Group LLP purchased a new stake in Bruker during the second quarter worth about $1,365,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Bruker during the 2nd quarter valued at approximately $1,999,000. Corient Private Wealth LP acquired a new stake in shares of Bruker during the 2nd quarter valued at approximately $233,000. Expect Equity LLC purchased a new stake in shares of Bruker during the 2nd quarter worth approximately $4,269,000. Finally, Primecap Management Co. CA purchased a new stake in Bruker during the second quarter worth $53,145,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. UBS Group assumed coverage on shares of Bruker in a report on Wednesday. They issued a “neutral” rating and a $65.00 price target on the stock. Guggenheim raised their price objective on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Zacks Research downgraded Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Wolfe Research assumed coverage on Bruker in a report on Monday, June 1st. They set a “peer perform” rating on the stock. Finally, JPMorgan Chase & Co. increased their target price on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bruker presently has an average rating of “Hold” and a consensus target price of $57.00.

Bruker Price Performance

BRKR stock opened at $54.43 on Thursday. The stock has a market capitalization of $8.29 billion, a price-to-earnings ratio of -77.76, a price-to-earnings-growth ratio of 1.79 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. Bruker Corporation has a 52-week low of $30.09 and a 52-week high of $65.30. The stock’s fifty day simple moving average is $58.57 and its 200-day simple moving average is $49.11.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same period in the prior year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s dividend payout ratio is currently -28.57%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.